MWNA
RNAC icon

Marshall Wace North America’s Cartesian Therapeutics RNAC Stock Holding History

Marshall Wace North America’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$7.61M Sell
60,934
-7,191
-11% -$868K 0.03% 408
2021
Q2 		$8.54M Sell
68,125
-28,482
-29% -$3.39M 0.04% 406
2021
Q1 		$13.1M Buy
96,607
+322
+0.3% +$40K 0.05% 342
2020
Q4 		$8.75M Hold
96,285
– – 0.04% 414
2020
Q3 		$7.16M Buy
96,285
+1,195
+1% +$91.6K 0.05% 331
2020
Q2 		$8.1M Buy
+95,090
New +$8.62M 0.05% 293

Other funds holding RNAC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Marshall Wace North America's RNAC Position: Q3 2021 in Review

Marshall Wace North America reduced its Cartesian Therapeutics (RNAC) stake by 11% in Q3 2021, selling an estimated $868K and leaving 60,934 shares worth $7.61M. The position accounts for 0.03% of the portfolio, ranked #408.

Marshall Wace North America first reported a position in RNAC in Q2 2020 and has held it in 6 quarters since. The position peaked at $13.1M in Q1 2021. 103 funds tracked by Wall St. Rank hold RNAC as of Q3 2021.

  • Marshall Wace North America held 60,934 shares of Cartesian Therapeutics worth $7.61M as of Q3 2021.
  • Marshall Wace North America sold 7,191 Cartesian Therapeutics shares in Q3 2021, an estimated $868K.
  • Cartesian Therapeutics made up 0.03% of Marshall Wace North America's portfolio in Q3 2021, its #408 holding.
  • Marshall Wace North America first reported a position in Cartesian Therapeutics in Q2 2020 and has held it in 6 quarters since.
  • Marshall Wace North America's Cartesian Therapeutics position peaked at $13.1M in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.